[1] 中华医学会血液学分会. 骨髓增生异常综合征诊断与治疗中国专家共识[J]. 中华血液学杂志, 2014,11(35):1024-1048. [2] Canaani J, Nagler A.Established and emerging targeted therapies in the myelodysplastic syndromes[J]. Expert Rev Hematol, 2016,9(10):997-1005. [3] Ades L, Itzykson R, Fenaux P.Myelodysplastic syndromes[J]. Lancet, 2014,383(9936):2239-2252. [4] Itzykson R, Fenaux P.Epigenetics of myelodysplastic syndromes[J]. Leukemia, 2014,28(3):497-506. [5] Qin Y Z, Zhang Y H, Qin X Y, et al.Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes[J]. Oncol Lett, 2017,13(4):2823-2830. [6] Zhang Q, Lin Z, Yin X, et al.In vitro and in vivo study of hydralazine, a potential anti-angiogenic agent[J]. Eur J Pharmacol, 2016,779:138-146. [7] Halby L, Champion C, Senamaud-Beaufort C, et al.Rapid synthesis of new DNMT inhibitors derivatives of procainamide[J]. Chemb-iochem, 2012,13(1):157-165. [8] Wang Y, Li Y, Liu X, et al.Genetic and epigenetic studies for determining molecular targets of natural product anticancer agents[J]. Curr Cancer Drug Targets, 2013,13(5):506-518. [9] Zwergel C, Valente S, Mai A.DNA Methyltransferases Inhibitors from Natural Sources[J]. Curr Top Med Chem, 2016,16(7):680-696. [10] Fulkerson C M, Dhawan D, Jones D R, et al.Pharmacokinetics and toxicity of the novel oral demethylating agent zebularine in laboratory and tumor bearing dogs[J]. Vet Comp Oncol, 2017,15(1):226-236. [11] Yun S, Vincelette N D, Abraham I, et al.Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials[J]. Clinical 7Epigenetics, 2016,8(1):1-9. [12] Nakamura K, Nakabayashi K, Htet Aung K, et al.DNA Methyltransferase Inhibitor Zebularine Induces Human Cholangiocarcinoma Cell Death through Alteration of DNA Methylation Status[J]. PLOS ONE, 2015,10(3):e120545. [13] Lee J, Kim Y, Sohn S K, et al.Benefits of hypomethylating therapy in IPSS lower-risk myelodysplastic syndrome patients: A retros-pective multicenter case series study[J]. Leukemia Research, 2017,60(60):135-144. [14] Gore S D, Fenaux P, Santini V, et al.A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial[J]. Haematologica, 2013,98(7):1067-1072. [15] Garcia-Manero G.Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management[J]. Am J Hematol, 2015,90(9):831-841. [16] Mahfouz R Z, Jankowska A, Ebrahem Q, et al.Increased CDA expression/activity in males contributes to decreased cytidine analog half-life and likely contributes to worse outcomes with 5-azacytidine or decitabine therapy[J]. Clin Cancer Res, 2013,19(4):938-948. [17] Chang C, Zhao Y, Xu F, et al.TP53 mutations predict decitabine-induced complete responses[J]. British Journal of Haematology, 2017,176(4):600-608. [18] Momparler R L.Pharmacology of 5-Aza-2'-deoxycytidine (deci-tabine)[J]. Seminars in Hematology, 2005,42(3 suppl 2):9-16. [19] Li X, Song Q, Chen Y, et al.Decitabine of reduced dosage in Chinese patients with myelodysplastic syndrome: a retrospective analysis[J]. PLoS One, 2014,9(4):e95473. [20] Li H, Wang L, Wu Y, et al.Very-Low-Dose Decitabine Is Effective in Treating Intermediate- or High-Risk Myelodysplastic Syndrome[J]. Acta Haematologica, 2017,138(3):168-174. [21] Ye L, Ren Y, Zhou X, et al.Decitabine priming prior to low-dose chemotherapy improves patient outcomes in myelodysplastic syndromes-RAEB: a retrospective analysis vs. chemotherapy alone[J]. Journal of Cancer Research and Clinical Oncology, 2017, 143(5):873-882. [22] rskov A D, Treppendahl M B, Skovbo A, et al. Hypomethylation and up-regulation of PD-1 in T cells by azacytidine in MDS/AML patients: A rationale for combined targeting of PD-1 and DNA methylation[J]. Oncotarget, 2015,6(11):9612-9626. [23] Prébet T, Gore S D, Esterni B, et al.Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure[J]. Journal of Clinical Oncology, 2011,29(24):3322-3327. [24] Sekeres M A.Managing patients with higher-risk myelodysplastic syndrome with stable disease on hypomethylating agents[J]. Leuk Lymphoma, 2015,56(12):3267-3269. [25] Komrokji R S.Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents[J]. Clinical Lymphoma Myeloma and Leukemia, 2015,15:S56-S59. [26] Loiseau C, Ali A, Itzykson R.New therapeutic approaches in myelodysplastic syndromes: Hypomethylating agents and lenalid-omide[J]. Exp Hematol, 2015,43(8):661-672. [27] Garcia-Manero G, Gore S, Kambhampati S.Efficacy and safety of extended dosing schedules of CC-486[J]. Leukemia, 2016(30):889-896. [28] Issa J J, Roboz G, Rizzieri D, et al.Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study[J]. oncology, 2015,16(9):1099-1110. [29] Kantarjian H M, Roboz G J, Kropf P L, et al.Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial[J]. Lancet Oncol, 2017,18(10):1317-1326. [30] Shahrabi S, Khosravi A, Shahjahani M, et al.Genetics and epigenetics of myelodysplastic syndromes and response to drug therapy: new insights[J]. Oncology Reviews, 2016,10(2):311. [31] Kuendgen A, Bug G, Ottmann O G, et al.Treatment of poor-risk myelodysplastic syndromes and acute myeloid leukemia with a combination of 5-azacytidine and valproic acid[J]. Clinical Epigenetics, 2011,2(2):389-399. [32] Issa J, Garcia-Manero G, Huang X, et al.Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia[J]. Cancer, 2015,121(4):556-561. [33] Candelaria M, Burgos S, Ponce M, et al.Encouraging results with the compassionate use of hydralazine/valproate (TRANSKRIP) as epigenetic treatment for myelodysplastic syndrome (MDS)[J]. Ann Hematol, 2017,96(11):1825-1832. |